Iterum Therapeutics plc

Listed Company

ITRMCIK 0001659323NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsL2IEFY ends Dec 31

Period

FY 2024

Revenue

—

Net Income

—

Total Assets

$44.59M

Equity

$-4.08M

Shares Out

44.66M

Op. Cash Flow

$-26.77M

Business

Iterum Therapeutics plc is a pharmaceutical company focused on developing and maximizing the commercial potential of ORLYNVAH™ and its sulopenem program, an oral and intravenous penem antibiotic for resistant gram-negative infections. Its main products and services center on ORLYNVAH™ (sulopenem etzadroxil with probenecid) as the oral formulation and an IV sulopenem formulation, supported by clinical development, regulatory filings and manufacturing programs. The company operates development, regulatory and potential commercialization efforts, including strategic partnering or direct launch plans. It targets the U.S. market following FDA approval and evaluates regulatory submissions and commercial options in Europe and other global markets, serving community and hospital distribution channels via third-party manufacturers and partners.

Summary from filing dated 2025-02-07

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Cost of sales	−254,000	—	—	—	—
Research and development	−10	−40	−18	−11	−21
General and administrative	−8	−7	−13	−14	−11
Total operating expenses	−19	−47	−30	−25	−32
Operating loss	−19	−47	−30	−25	−32
Interest expense, net	−3	−1	−2	−6	−15
Adjustments to fair value of derivatives	−3	11	5	−61	−2
Cancellation of share options	—	—	−17	—	—
Other (expense) / income, net	−47,000	82,000	503,000	195,000	213,000
Total other (expense) / income	−6	10	−14	−66	−19
Loss before income taxes	−25	−38	−44	−91	−51
Income tax expense	−240,000	−613,000	−301,000	−705,000	−743,000
Net loss	−25	−38	−44	−92	−52
Net loss per share - basic	−1.26	−2.96	−3.63	−8.41	−32.49
Net loss per share - diluted	−1.26	−2.96	−3.63	−8.41	−32.49
Weighted average ordinary shares outstanding - basic	20	13	12	11	2
Weighted average ordinary shares outstanding - diluted	20	13	12	11	2
Unrealized (loss) / income on marketable securities	−1,000	351,000	−350,000	—	—
Comprehensive loss	−25	−38	−45	−92	−52

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Cash and cash equivalents	24	6	21	27	15
Short-term investments	0	18	40	54	0
Prepaid expenses and other current assets	614,000	2	1	2	7
Income taxes receivable	48,000	38,000	302,000	—	—
Total current assets	25	26	62	83	21
Intangible asset, net	20	—	2	3	—
Property and equipment, net	23,000	51,000	69,000	91,000	421,000
Restricted cash	34,000	34,000	34,000	64,000	248,000
Other assets	5,000	578,000	3	5	11
Total assets	45	26	67	92	33
Accounts payable	251,000	5	3	878,000	816,000
Accrued expenses	3	8	4	1	2
Exchangeable notes	14	—	—	—	—
Other current liabilities	240,000	761,000	2	3	4
Total current liabilities	18	14	9	13	42
Long-term debt - Exchangeable notes	—	11	—	—	—
Long-term debt - Pfizer Promissory Note	20	—	—	—	—
Royalty-linked notes	11	8	18	18	13
Other liabilities	0	188,000	1	3	6
Total liabilities	49	33	39	41	83
Commitments and contingencies (Note 16)	—	—	—	—	—
Undesignated preferred shares, $0.01 par value per share: 100,000,000 shares authorized at December 31, 2024 and December 31,2023; no shares issued at December 31, 2024 and December 31, 2023	—	—	—	—	—
Ordinary shares, $0.01 par value per share: 80,000,000 shares authorized at December 31, 2024 and December 31, 2023, 31,534,233 shares issued at December 31, 2024; 13,499,003 shares issued at December 31, 2023	315,000	135,000	126,000	122,000	494,000
Additional paid-in capital	482	455	451	429	236
Accumulated deficit	−486	−461	−423	−378	−287
Accumulated other comprehensive gain	0	1,000	−350,000	—	—
Total shareholders' deficit	−4	−6	28	50	−51
Total liabilities and shareholders' deficit	45	26	67	92	33

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Net loss	−25	−38	−44	−92	−52
Depreciation	30,000	31,000	84,000	391,000	161,000
Amortization	254,000	2	2	2	—
Lease termination adjustments	—	473,000	—	—	—
Share-based compensation expense	363,000	784,000	5	4	3
Amortization of short-term investments	−352,000	−1	−183,000	636,000	—
Interest on short-term investments	1,000	55,000	−55,000	−290,000	—
Amortization of debt discount and deferred financing costs	2	2	2	4	11
Other	4	2	2	3	752,000
Prepaid expenses and other current assets	−3	−3	−2	1	2
Other assets	17,000	322,000	—	−8,000	308,000
Accounts payable	−5	2	2	63,000	−15
Accrued expenses	−5	3	3	−662,000	−11
Income taxes	155,000	271,000	−510,000	271,000	−120,000
Other liabilities	−385,000	−354,000	−708,000	−1	−1
Net cash used in operating activities	−27	−39	−18	−16	−55
Purchases of property and equipment	−2,000	−13,000	−62,000	−61,000	−11,000
Purchases of short-term investments	−12	−41	−46	−67	—
Proceeds from sale of short-term investments	31	65	60	13	—
Net cash provided by investing activities	18	23	14	−55	−11,000
Repayments of long-term bank debt	—	—	−2	−7	−6
Proceeds from issuance of ordinary shares, net of transaction costs	27	1	433,000	90	—
Net cash provided by / (used in) financing activities	27	1	−2	83	64
Effect of exchange rates on cash and cash equivalents	−75,000	−61,000	−50,000	4,000	−11,000
Net increase / (decrease) in cash, cash equivalents and restricted cash	18	−15	−6	13	10
Income tax paidU.S.	220,000	401,000	821,000	435,000	120,000
Interest paid	—	—	22,000	416,000	996,000
Non-cash proceeds - Pfizer Promissory Note	20	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro